News & Presentations

UPCOMING EVENTS

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – January

AR-13324-CS208 Japan Phase 2 Study Topline Results

Topline Results from Rhopressa® (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST)

News Releases

TOP